These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 25614144)
1. A pharmacokinetic comparison of anrukinzumab, an anti- IL-13 monoclonal antibody, among healthy volunteers, asthma and ulcerative colitis patients. Hua F; Ribbing J; Reinisch W; Cataldi F; Martin S Br J Clin Pharmacol; 2015 Jul; 80(1):101-9. PubMed ID: 25614144 [TBL] [Abstract][Full Text] [Related]
2. Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study. Reinisch W; Panés J; Khurana S; Toth G; Hua F; Comer GM; Hinz M; Page K; O'Toole M; Moorehead TM; Zhu H; Sun Y; Cataldi F Gut; 2015 Jun; 64(6):894-900. PubMed ID: 25567115 [TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease. Rosario M; Dirks NL; Gastonguay MR; Fasanmade AA; Wyant T; Parikh A; Sandborn WJ; Feagan BG; Reinisch W; Fox I Aliment Pharmacol Ther; 2015 Jul; 42(2):188-202. PubMed ID: 25996351 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and C-reactive protein modelling of anti-interleukin-6 antibody (PF-04236921) in healthy volunteers and patients with autoimmune disease. Li C; Shoji S; Beebe J Br J Clin Pharmacol; 2018 Sep; 84(9):2059-2074. PubMed ID: 29776017 [TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetics and Pharmacodynamics of Ontamalimab (SHP647), a Fully Human Monoclonal Antibody Against Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1), in Patients With Ulcerative Colitis or Crohn's Disease. Wang Y; Marier JF; Lavigne J; Kassir N; Martin P J Clin Pharmacol; 2020 Jul; 60(7):903-914. PubMed ID: 32119128 [TBL] [Abstract][Full Text] [Related]
6. Population Pharmacokinetic Modeling of Benralizumab in Adult and Adolescent Patients with Asthma. Yan L; Wang B; Chia YL; Roskos LK Clin Pharmacokinet; 2019 Jul; 58(7):943-958. PubMed ID: 30854591 [TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials. Diao L; Hang Y; Othman AA; Nestorov I; Tran JQ Clin Pharmacokinet; 2016 Aug; 55(8):943-55. PubMed ID: 26873229 [TBL] [Abstract][Full Text] [Related]
8. Population Pharmacokinetics and Exposure-Response Modeling of Golimumab in Adults With Moderately to Severely Active Ulcerative Colitis. Adedokun OJ; Xu Z; Liao S; Strauss R; Reinisch W; Feagan BG; Sandborn WJ Clin Ther; 2020 Jan; 42(1):157-174.e4. PubMed ID: 31982148 [TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetics of Galcanezumab, an Anti-CGRP Antibody, Following Subcutaneous Dosing to Healthy Individuals and Patients With Migraine. Kielbasa W; Quinlan T J Clin Pharmacol; 2020 Feb; 60(2):229-239. PubMed ID: 31482569 [TBL] [Abstract][Full Text] [Related]
10. Population-Pharmacokinetic Modeling of Tildrakizumab (MK-3222), an Anti-Interleukin-23-p19 Monoclonal Antibody, in Healthy Volunteers and Subjects with Psoriasis. Jauslin P; Kulkarni P; Li H; Vatakuti S; Hussain A; Wenning L; Kerbusch T Clin Pharmacokinet; 2019 Aug; 58(8):1059-1068. PubMed ID: 30915660 [TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics and Pharmacodynamics of Benralizumab in Healthy Volunteers and Patients With Asthma. Wang B; Yan L; Yao Z; Roskos LK CPT Pharmacometrics Syst Pharmacol; 2017 Apr; 6(4):249-257. PubMed ID: 28109128 [TBL] [Abstract][Full Text] [Related]
12. Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthma. Zhu R; Zheng Y; Dirks NL; Vadhavkar S; Jin JY; Peng K; Holweg CTJ; Olsson J; Matthews JG; Putnam WS Pulm Pharmacol Ther; 2017 Oct; 46():88-98. PubMed ID: 28843617 [TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetic analysis of etrolizumab in patients with moderately-to-severely active ulcerative colitis. Moein A; Lu T; Jönsson S; Ribbing J; Kassir N; Zhang W; Sperinde G; Zhang R; Tang M; Oh YS; Bruno R; Zhu R CPT Pharmacometrics Syst Pharmacol; 2022 Sep; 11(9):1244-1255. PubMed ID: 35851998 [TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetic modeling of oral brepocitinib in healthy volunteers and patients with immuno-inflammatory diseases. Maleki F; Clark E; Banfield C; Byon W; Nicholas T CPT Pharmacometrics Syst Pharmacol; 2024 Apr; 13(4):551-562. PubMed ID: 38332554 [TBL] [Abstract][Full Text] [Related]
15. Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis. Vong C; Martin SW; Deng C; Xie R; Ito K; Su C; Sandborn WJ; Mukherjee A Clin Pharmacol Drug Dev; 2021 Mar; 10(3):229-240. PubMed ID: 33513294 [TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetic Analysis of Dorzagliatin in Healthy Subjects and Patients with Type 2 Diabetes Mellitus. Wang K; Feng L; Zhang J; Zou Q; Xu F; Sun Z; Tang F; Chen L Clin Pharmacokinet; 2023 Oct; 62(10):1413-1425. PubMed ID: 37537410 [TBL] [Abstract][Full Text] [Related]
17. Population PK and IgE pharmacodynamic analysis of a fully human monoclonal antibody against IL4 receptor. Kakkar T; Sung C; Gibiansky L; Vu T; Narayanan A; Lin SL; Vincent M; Banfield C; Colbert A; Hoofring S; Starcevic M; Ma P Pharm Res; 2011 Oct; 28(10):2530-42. PubMed ID: 21604075 [TBL] [Abstract][Full Text] [Related]
18. A mechanistic PK/PD model for two anti-IL13 antibodies explains the difference in total IL-13 accumulation observed in clinical studies. Tiwari A; Kasaian M; Heatherington AC; Jones HM; Hua F MAbs; 2016 Jul; 8(5):983-90. PubMed ID: 27049478 [TBL] [Abstract][Full Text] [Related]
19. Effects of demographic variables on vorozole pharmacokinetics in healthy volunteers and in breast cancer patients. Piotrovsky VK; Huang ML; Van Peer A; Langenaecken C Cancer Chemother Pharmacol; 1998; 42(3):221-8. PubMed ID: 9685057 [TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration. Othman AA; Tran JQ; Tang MT; Dutta S Clin Pharmacokinet; 2014 Oct; 53(10):907-18. PubMed ID: 25212703 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]